Nature Medicine
3, 639 - 645 (1997)
doi:10.1038/nm0697-639
ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agentsCarla Heise1, Adam Sampson-Johannes1, Angelica Williams1, Frank Mccormick, Daniel D. Von Hoff2
& David H. Kirn1, 3
1ONYX Pharmaceuticals 3031 Research Drive Richmond, California 94806, USA
2Cancer Therapy and Research Center San Antonio, TX 78245, USA
3Correspondence should be addressed to D.H.K. The 55-kilodalton (kDa) protein from the E1B-region of adenovirus binds to and inactivates the p53 gene, which is mutated in half of human cancers. We have previously shown that the replication and cytopathogenicity of an E1B, 55-kDa gene-attenuated adenovirus, ONYX-015, is blocked by functional p53 in RKO and U2OS carcinoma lines. We now report that normal human cells were highly resistant to ONYX-015-mediated, replication-dependent cytolysis. In contrast, a wide range of human tumor cells, including numerous carcinoma lines with either mutant or normal p53 gene sequences (exons 5−9), were efficiently destroyed. Antitumoral efficacy was documented following intratumoral or intravenous administration of ONYX-015 to nude mousehuman tumor xenografts; efficacy with ONYX-015 plus chemotherapy (cisplatin, 5-fluorouracil) was significantly greater than with either agent alone.
REFERENCES
- Lowe, S.W., Ruley, H.E., Jacks, T. & Housman, D.E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74, 957−967 (1993). | Article | PubMed | ISI | ChemPort |
- Fujiwara, T. et al. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res. 54, 2287−2291 (1994). | PubMed | ISI | ChemPort |
- Lowe, S.W. et al. p53 status and the efficacy of cancer therapy in vivo. Science 266, 807−810 (1994). | PubMed | ISI | ChemPort |
- Fearon, E.R., Hamilton, S.R. & Vogelstein, B. Clonal analysis of human colorectal tumors. Science 238, 193−197 (1990).
- Brennan, J.A. et al. Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 332, 429−435 (1995). | Article | PubMed | ISI | ChemPort |
- Chang, F., Syrjanen, S. & Syrjanen, K. Implications of the p53 tumor-suppressor gene in clinical oncology. J. clin. Oncol. 13, 1009−1022 (1995). | PubMed | ISI | ChemPort |
- Bergh, J., Norberg, T., Sjögren, S., Lindgren, A. & Holmberg, L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nature Med. 1, 1029−1034 (1995). | Article | PubMed | ISI | ChemPort |
- Eliopoulos, A.G. et al. The control of apoptosis and drug resistance in ovarian cancer: Influence of p53 and Bcl-2. Oncogene 11, 1217−1228 (1995). | PubMed | ISI | ChemPort |
- Debbas, M. & White, E. Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes Dev. 7, 546−554 (1993). | Article | PubMed | ISI | ChemPort |
- Grand, R.J., Grant, M.L. & Gallimore, P.H. Enhanced expression of p53 in human cells infected with mutant adenoviruses. Virology 203, 229−240 (1994). | Article | PubMed | ISI | ChemPort |
- Lowe, S.W., Ruley, H.E., Jacks, T. & Housman, D.E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74, 957−967 (1993). | Article | PubMed | ISI | ChemPort |
- Lechner, M.S. et al. Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53-mediated repression of transcription. EMBO J. 11, 3045−3052 (1992). | PubMed | ISI | ChemPort |
- Gannon, J.V. & Lane, D.P. p53 and DNA polymerase alpha compete for binding to SV40 T antigen. Nature 329, 456−458 (1987). | Article | PubMed | ISI | ChemPort |
- Barker, D.D. & Berk, A.J. Adenovirus proteins from both El B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology 156, 107−121 (1987). | Article | PubMed | ISI | ChemPort |
- Slichenmeyer, W.J., Nelson, W.G., Slebos, R.J. & Kastan, M.B. Loss of a p53-associated G1 checkpoint does not decrease cell survival Cancer Res. 53 4164−4169 (1993 | PubMed | ISI | ChemPort |
- Bischoff, J.R. et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274, 373−376 (1996). | Article |
- MacCallum, D. et al. The p53 response to ionizing radiation in adult and developing tissues. Oncogene 13, 2575−2587 (1996). | PubMed | ISI | ChemPort |
- Brown, B. et al. Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int. J. Cancer 55, 678−684 (1993). | PubMed | ISI | ChemPort |
- Li, C., Nagasawa, H., Dahlberg, W. & Little, J. Diminished capacity for p53 in mediating a radiation-induced G1 arrest in established human tumor cell lines. Oncogene 11, 1885−1892 (1995). | PubMed | ISI | ChemPort |
- Wills, K.N. et al. Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Hum. Gene Ther. 5, 1079−88 (1994). | PubMed | ISI | ChemPort |
- Clayman, G.L. et al. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res. 55, 1−6 (1995). | PubMed | ISI | ChemPort |
- Roth, J. et al. p53 as a target for cancer vaccines: Recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge. Proc. Natl. Acad. Sci. USA 93, 4781−4786 (1996). | Article | PubMed | ChemPort |
- Kim, D.H. Replicating oncolytic viruses: An overview. Expert Opin. Invest. Invest Drugs 5, 753−762 (1996).
- Sanchez-Prieto, R. et al. Carcinoma cells become sensitive to DNA-damaging agents by the expression of the adenovirus E1 A gene. Oncogene 13, 1083−1092 (1996). | PubMed | ISI |
- Debbas, M. & White, E. Wild-type p53 mediates apoptosis by El A, which is inhibited by E1 B. Genes Dev. 7, 546−554 (1993). | Article | PubMed | ISI | ChemPort |
- Engelhardt, J.F. et al. Direct gene transfer of human CFTR into human bronchial epithelia of xenografts with E1-deleted adenoviruses. Nature Genet. 4, 27−34 (1993). | PubMed | ISI | ChemPort |
- Wilson, J.M., Engelhardt, J.F., Grossman, M., Simon, R.H. & Yang, Y. Gene therapy of cystic fibrosis lung disease using E1 deleted adenoviruses: A phase I trail. Hum. Gene Ther. 5, 501−519 (1994). | PubMed | ISI | ChemPort |
- Fearon, E.R., Itaya, T., Hunt, B., Vogelstein, B. & Frost, P. Induction in a murine tumor of immunogenic tumor variants by transfection with a foreign gene. Cancer Res. 48, 2975−2980 (1988). | PubMed | ISI | ChemPort |
- Zinkernagel, R.M. Immunology taught by viruses. Science 271, 173−178 (1996). | PubMed | ISI | ChemPort |
- Jain, R.K. Barriers to drug delivery in solid tumors. Sci. Am. 271, july, 58−65 (1994). | PubMed | ISI | ChemPort |
- Dvorak, H.F., Nagy, J.A., Dvorak, J.T. & Dvorak, A.M. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am. J. Pathol. 133, 95−109 (1988). | PubMed | ISI | ChemPort |
- Ginsberg, H.S. & Prince, G.A. The molecular basis of adenovirus pathogenesis. Infect Agents Dis. 3, 1−8 (1994). | PubMed | ISI | ChemPort |
- Scheffner, M., Munger, K., Byrne, J.C. & Howley, P.M. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc. Natl. Acad. Sci. USA 88, 5523−5527 (1991). | PubMed | ChemPort |
- Wang, N., To, H., Lee, W. & Lee, E. Tumor suppressor activity of Rb and p53 genes in human breast carcinoma cells. Oncogene 8, 279−288 (1993). | PubMed | ISI | ChemPort |
- Rodrigues, N.R. et al. p53 mutations in colorectal cancer. Proc. Natl. Acad. Sci. USA 87, 7555−7559 (1990). | PubMed | ChemPort |
- Van Meir, E.G. et al. Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res. 54, 649−652 (1994). | PubMed | ChemPort |
- Hsu, I.C. et al. p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer lines. Carcinogenesis 14, 987−992 (1993). | PubMed | ISI | ChemPort |
- Yaginuma, Y. & Westphal, H. Abnormal structure and function of the p53 gene in human ovarian carcinoma cell lines. Cancer Res. 52, 4196−4199 (1992). | PubMed | ISI | ChemPort |
- Ruggeri, B. et al. Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumor-suppressor genes. Oncogene 7, 1503−1511 (1992). | PubMed | ISI | ChemPort |
- Hsu, I.C. et al. p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines. Carcinogenesis 14, 987−992 (1993). | PubMed | ISI | ChemPort |
- Waldman, T., Kinzler, K.W. & Vogelstein, B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. 55, 5187−5190 (1995). | PubMed | ISI | ChemPort |
|
